Roberts Glore & Co. Inc. IL Makes New $4.94 Million Investment in Abbott Laboratories $ABT

Roberts Glore & Co. Inc. IL acquired a new stake in Abbott Laboratories (NYSE:ABT) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 54,490 shares of the healthcare product maker’s stock, valued at approximately $4,944,000. Abbott Laboratories makes up 1.2% of Roberts Glore & Co. Inc. IL’s holdings, making the stock its 16th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in ABT. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Norges Bank purchased a new position in Abbott Laboratories in the 4th quarter valued at about $2,938,892,000. Legal & General Group Plc purchased a new stake in Abbott Laboratories during the 2nd quarter worth approximately $1,082,524,000. Flossbach Von Storch SE purchased a new stake in Abbott Laboratories during the 2nd quarter worth approximately $902,938,000. Finally, Jupiter Topco LLC acquired a new position in shares of Abbott Laboratories during the second quarter valued at approximately $732,788,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $110.52 on Thursday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The stock has a market cap of $191.24 billion, a PE ratio of 35.77, a P/E/G ratio of 2.02 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock has a 50 day moving average price of $103.83 and a 200 day moving average price of $100.09.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 earnings per share. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. UBS Group decreased their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Bank of America lowered their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.